Skip to main content

Advertisement

Fig. 2 | BMC Cancer

Fig. 2

From: A pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers

Fig. 2

Distinctive pharmacokinetic profiles of rapid, normal and slow metabolizers. a Mean peak plasma ATV concentration-time curves after a single 80-mg dose of ATV of the three metabolizer phenotypes. Data shown are mean ± standard error (SE) concentrations. b Distributions of metabolizer phenotypes with regard to Cmax-AUC0>-t values. For both a xand b: rapid metabolizers in red, normal in green, and slow ones in blue

Back to article page